Recognizing Pinch Purpura as the First Manifestation of Light-chain Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Scientific Articles

Recognizing Pinch Purpura as the First Manifestation of Light-chain Amyloidosis

key information

source: Turkish Journal of Haematology

year: 2018

authors: Öztürk E, Akay MO, Ferhanoğlu B

summary/abstract:

A 74-year-old female presented with a 6-month history of easy bruising as manifested by purpura after minor trauma to her face. Her physical examination was unremarkable except for the presence of pinch purpura scattered on her face. Laboratory tests showed leukocytes of 8100/µL, hemoglobin of 11.2 g/dL, platelets of 208,000/µL, prothrombin time of 11 s (normal range: 11.2-13.0 s), activated partial thromboplastin time of 25 s (normal range: 23.0-33.0 s), and erythrocyte sedimentation rate of 72 mm/h. Upon further workup, the presence of IgG lambda monoclonal gammopathy of the serum and lambda monoclonal light chain was found in urine immunofixation electrophoresis. 
 
Bone marrow biopsy revealed 7% lambda-restricted plasma cell infiltration, showing green birefringence with Congo red stain and vascular amyloid P deposition. There were no CRAB symptoms, organ dysfunction, or organomegaly. Echocardiography and pro-B-type natriuretic peptide results were normal. A diagnosis of amyloid light-chain (AL) amyloidosis initially presenting with purpura was made and a chemotherapy regimen of bortezomib and dexamethasone was started. Complete remission was achieved after six courses of chemotherapy and the purpuric lesions disappeared.
 
organization: Clinic of Hematology, Turkey

DOI: 10.4274/tjh.2018.0016

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close